BioInvent International AB
19
3
5
10
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
21.1%
4 terminated/withdrawn out of 19 trials
71.4%
-15.1% vs industry average
0%
0 trials in Phase 3/4
10%
1 of 10 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (19)
A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Role: lead
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
Role: lead
A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors
Role: collaborator
Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma
Role: lead
BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors
Role: lead
A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL
Role: lead
BI-1607 in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors
Role: lead
A Phase II Study of BI-505 in Smoldering Multiple Myeloma
Role: lead
Phase I Study on Monoclonal Antibody TB-403 Directed Against PlGF in Patients With Solid Tumours
Role: lead
BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia
Role: collaborator
A Phase I/II Study of BI-505 in Conjunction With Autologous Stem Cell Transplant in Multiple Myeloma
Role: lead
A Study to Evaluate the Safety, Tolerability, and Activity of Intravenous MLDL1278A in Patients on Standard-of-Care Therapy for Stable Atherosclerotic Cardiovascular Disease (GLACIER)
Role: collaborator
Single Intravenous Administration of TB-402 for the Prophylaxis of Venous Thromboembolic Events (VTE) After Total Knee Replacement Surgery
Role: collaborator
Effects of LMWH in Healthy Subjects Treated With TB-402 and Effects of TB-402 in Healthy Subjects Treated With Warfarin
Role: collaborator
Effect of Recombinant FVIII in Healthy Male Subjects Treated With TB-402
Role: collaborator
A Phase I Study of Monoclonal Antibody TB-402 in Healthy Male Volunteers
Role: collaborator
A Study of a Human Anti-Intercellular Adhesion Molecule-1 Monoclonal Antibody, in Patients With Multiple Myeloma
Role: lead
Bioavailability Study of MLDL1278A After Subcutaneous and Intravenous Administration in Healthy Subjects
Role: lead
Single IV Administration of TB-402 for Prophylaxis of Venous Thromboembolic Events (VTE) After Total Hip Replacement Surgery
Role: collaborator
All 19 trials loaded